Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05023018 · ClinicalTrials.gov registry record · Phase 2
NEO100 and High-Grade Meningioma
A Phase 2 study of Residual, Progressive or Recurrent Grade II or III Meningioma, sponsored by Neonc Technologies.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT05023018 is a Phase 2 study of Residual, Progressive or Recurrent Grade II or III Meningioma that is actively recruiting participants, run by Neonc Technologies. The registered enrollment target is 30 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT05023018, a Phase 2 study of Residual, Progressive or Recurrent Grade II or III Meningioma, is actively recruiting participants, sponsored by Neonc Technologies.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma. There will be up to 30 patients enrolled in this study to have 29 evaluable patients. NEO100 will be self-administered four times daily on a 28-day treatment cycle until disease progression, death or patient withdraw from study for any reason, whichever occurs first.
Conditions Studied
Interventions
- DRUG NEO100
Study Locations (3)
California
- University of Southern California - Los Angeles
- Saint John Cancer Institute - Santa Monica
Texas
- Baylor Scott and White - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-07-01 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05023018
The ClinicalTrials.gov registry entry for NCT05023018 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neonc Technologies, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Residual, Progressive or Recurrent Grade II or III Meningioma appearing as the primary indexed condition, and to 1 intervention - of which NEO100 is the first listed.
NCT05023018 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Texas.
Frequently Asked Questions
What is clinical trial NCT05023018 about?
NCT05023018 is a clinical study titled "NEO100 and High-Grade Meningioma". This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed prog...
What is the current status of trial NCT05023018?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-07-01. Estimated completion is 2027-06-30.
What conditions does trial NCT05023018 study?
This clinical trial studies the following conditions: Residual, Progressive or Recurrent Grade II or III Meningioma.
What interventions are being tested in trial NCT05023018?
The interventions under investigation include: NEO100 (DRUG).
Who is sponsoring clinical trial NCT05023018?
This trial is sponsored by Neonc Technologies, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05023018 being conducted?
This trial has 3 study locations across California, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.